Initiating thromboprophylaxis with low molecular weight heparin and transitioning to oral rivaroxaban
Roger M. Mills(Janssen (Belgium)), Peter Wildgoose(Janssen (United States)), Lisa K. Jennings(Saint Luke's Health System), Richard Berkowitz, C.V. Damaraju(Janssen (United States))
Cited by 0
Related Papers
Reflex Increase in Coronary Vascular Resistance in Patients with Ischemic Heart Disease
|New England Journal of Medicine|1976|480
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
|Journal of the American College of Cardiology|1999|323
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
|The Lancet|2009|298
Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis
|New England Journal of Medicine|2003|278